CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

ClinicalTrials.gov ID: NCT00290472

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00290472. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of CCI-779 in B-cell Lymphoma and CLL

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Drugs used in chemotherapy, such as CCI-779, work in different ways to stop cancer cells from dividing so they stop growing or die. This phase II trial is studying how well CCI-779 works in treating patients with recurrent or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

Study identification

NCT ID: NCT00290472
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 89 participants

Conditions and interventions

Conditions

Interventions

temsirolimus Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2004 (Type not available)
Primary completion: Apr 2010 (Actual)
Completion: Apr 2010 (Actual)
Last update posted: May 23, 2014

2004 – 2010

United States locations

U.S. sites: 13
U.S. states: 6
U.S. cities: 13

Facility	City	State	ZIP	Site status
University of Chicago	Chicago	Illinois	60637	—
Decatur Memorial Hospital	Decatur	Illinois	62526	—
Evanston Hospital CCOP	Evanston	Illinois	60201	—
Ingalls Memorial Hospital	Harvey	Illinois	60426	—
Adventist La Grange Memorial Hospital	La Grange	Illinois	60525	—
Loyola University Medical Center	Maywood	Illinois	60153	—
Central Illinois Hematology Oncology Center	Springfield	Illinois	60702	—
Fort Wayne Medical Oncology and Hematology Inc-Parkview	Fort Wayne	Indiana	46845	—
Northern Indiana Cancer Research Consortium	South Bend	Indiana	46601	—
University of Iowa	Iowa City	Iowa	52242	—
Oncology Care Associates PLLC	Saint Joseph	Michigan	49085	—
M D Anderson Cancer Center	Houston	Texas	77030	—
Froedtert and the Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00290472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 23, 2014 · Synced Nov 13, 2026